What’s New!
A recipe for success: How to thrive in Southeast Asia alternative protein market
Singapore has taken bold steps in accelerating innovation in the agrifood landscape in the recent years. For instance, while global regulators grappled with how to regulate cell-based foods, Singapore Food Agency (SFA) broke the impasse by becoming the first to grant regulatory approval for cell-based meat in 2021.
What to watch in the biomedical space over the next five years
The pandemic has brought the spotlight onto the healthcare and biomedical sectors, driving unprecedented enthusiasm in the relatively unknown field of mRNA innovations, and bolstering growth in digital health. Yet, the silver lining has dulled investors’ sentiments post-COVID. Increasingly, investors have become more cautious against macroeconomic headwinds, and many are expecting a correction in company valuations across all sectors.
WalkMe Establishes Asia Pacific Headquarters in Singapore
WalkMe, a leading provider of digital adoption platforms, announced the opening of its Asia Pacific headquarters in Singapore. The office was officially opened by Raphael Sweary, President and Co-founder, WalkMe at an exclusive event with senior executives from EDBI and IMDA.
The Sustainable Recipe to Feed the World
Dive into China and Southeast Asia's agrifood landscape, and what the future holds
- 12 Sep 2022
The Perks of Investing in Real Time Data
A video interview by Singapore Business Review featuring Deb Dutta (DataStax) and Paul Ng (EDBI) on how real time data applications can help organisations innovate and adopt technologies to build a smarter Singapore.
- 7 Sep 2022
Pindrop Continues to Grow, Expands its Footprint into APAC
Pindrop, a global technology leader offering security, identity, and intelligence for every voice, today announced its expansion into the Asia-Pacific region, with entry into Singapore as its first move.
- 6 Sep 2022
DataStax Secures $115 Million Investment led by Goldman Sachs Asset Management
DataStax, the real-time data company, announced that it has secured $115 million in funding led by the Growth Equity business within Goldman Sachs, with participation from Rokos Capital and Singapore-based global investor EDBI.
- 15 Jun 2022
Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the close of a US$126 million Series A financing round.
- 9 Jun 2022
Aspen Neuroscience Announces $147.5 Million Series B Financing, led by GV, LYFE Capital and Revelation Partners
Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease, announced the close of its Series B funding round of $147.5 million.
- 9 May 2022
Singapore’s Neuron Mobility Triples its Global Operations and Raises US$43.5 Million to Fuel Rapid International Expansion and Accelerate Tech Leadership
Neuron Mobility, Canada’s fastest-growing shared e-scooter and e-bike operator, announces it has successfully raised US$43.5 million in Series B funding. This follows 19 months of significant growth and brings the company’s total funding to US$77.7 million.
- 27 Apr 2022
WalkMe Establishes Asia Pacific Headquarters in Singapore
WalkMe, a leading provider of digital adoption platforms, announced the opening of its Asia Pacific headquarters in Singapore. The office was officially opened by Raphael Sweary, President and Co-founder, WalkMe at an exclusive event with senior executives from EDBI and IMDA.
- 27 Apr 2022
Ambiq Expands to Singapore with a New Technology Design Center
Ambiq®, a leading developer of ultra-low-power semiconductor solutions that deliver a multifold increase in energy efficiency, announces the grand opening of its new Technology Design Center in Singapore.
- 26 Apr 2022
RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity
RVAC Medicines, an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group, announced the completion of its series B financing, bringing the company’s total funds raised since its inception in June 2021 to US$140 million.
- 26 Apr 2022
